Platelet Rich Plasma VS Platelet Fibrin Plasma in Treatment of Diabetes Related Wound：a Randomized Controlled Trial

Inclusion Criteria: 1. The patient is aged 18-80 years old; 2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%; 3. diabetes wounds with poor healing or prolonged healing need standard wound treatment; 4. There is no disseminated infection or the disseminated infection has been controlled; 5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met; 6. Voluntarily sign an informed consent form; Exclusion Criteria: 1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet; 2. Severe ischemia of the wound surface, unable to seek medical attention or not yet corrected; 3. Uncontrolled systemic or disseminated infections; 4. Blood glucose is out of control or not yet effectively controlled; 5. Blood system diseases with uncorrected coagulation dysfunction or platelet dysfunction; 6. There is active bleeding inside the wound, and routine basic treatment plans cannot be implemented; 7. Platelets ≤ 80 × 10\^9, hemoglobin\<90g/L; 8. Patients with advanced malignant tumors; 9. Active period of autoimmune diseases; 10. The patient is unable to cooperate or has mental disorders; 11. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.